ADVERTISEMENT

Medical News

Novel Nasal Spray for Acute Migraine Disappoints in Phase 3 Trial

Megan Brooks   |   15 November 2022
View more articles on:

An investigational dihydroergotamine nasal spray for the acute treatment of migraine failed to meet its co-primary endpoints in a late-stage study, according to topline results announced by the developer.

STS101 (Satsuma Pharmaceuticals) was not statistically superior to placebo for freedom from pain and most bothersome symptom 2 hours after dosing in the SUMMIT phase...

          

November Challenge

Ends in 1d 6h
left
right

Topic Challenges

left
right